Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

namodenoson

An orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity. Namodenoson selectively binds to and activates the cell surface-expressed A3AR, deregulating Wnt and NF-kB signal transduction pathways downstream, which may result in apoptosis of A3AR-expressing tumor cells. A3AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of various solid tumor cell types, including hepatocellular carcinoma (HCC) cells, and plays an important role in cellular proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:A3AdR agonist CF102
adenosine receptor A3 agonist CF102
Abbreviation:2-Cl-IB-MECA
C-Ibza-MU
Code name:CF102
Chemical structure:2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
beta-D-ribofuranuronamide, 1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search